Neurovalens

Neurovalens develops non-invasive neurostimulation medical devices for neurological conditions.

Belfast, UK—Founded 2015

£9.7MTotal raised

Neurovalens is a health technology business that develops non-invasive neurostimulation medical devices to treat conditions such as diabetes, insomnia, anxiety and obesity.

Founders

Jason McKeown

CEO and co-founder

Jason brings medical and academic experience as the chief executive of Neurovalens, alongside visiting roles at Stanford University and the University of California, San Diego.

Investors

Series A20 July 2020
£5.1M
IQ CapitalLeadFollow-on
WA
Wharton Asset Management Company
Angel CoFundFollow-on
Techstart VenturesFollow-on
CI
Co-Fund II
Future Fund
Series A19 March 2019
£4.6M
WA
Wharton Asset ManagementLead
IQ Capital
Techstart Ventures
CF
Clarendon Fund Management
BP
Beltrae Partners
Angel CoFund

Funding history

Series A20 July 2020

£5.1M

Neurovalens raises £5.1m in a Series A follow-on round led by IQ Capital to advance medical device approvals

The financing will support clinical trials, product development and team expansion as the business pursues international regulatory approvals.

Series A19 March 2019

£4.6M

Neurovalens raises £4.6m Series A funding led by Wharton Asset Management to expand medical trials.

The Belfast-based health technology firm secured Series A backing from investors including Wharton Asset Management and IQ Capital to advance its neurological research and medical trials.